A replica of a woman's brain aneurysm allowed doctors to practice several times before operating on her.» Read More
Comedian Jon Stewart took to “The Daily Show’s” desk for the last time, yet he didn’t leave without giving one charity a gift they’d never forget.
Estimates of annual spending on PCSK9 drugs are as high as $150 billion, but drugmakers expect much lower.
Britain's competition watchdog alleged that U.S. drugmaker Pfizer and Flynn Pharma had breached competition law.
A slowdown in the Chinese economy hasn’t deterred pharmaceutical giant Novo Nordisk from expanding its local sales efforts.
Watch the founder of Sproutel pitch his start-up to a panel of experts on CNBC.
Discount retail chain CVS will no longer include Pfizer's Viagra in its list of drug insurance benefits, CNBC confirmed on Wednesday.
For health insurers, government health programs have become an increasingly important part of their business.
A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?
There were sharp decreases among uninsured people in Texas and California, but the rate among Hispanics continues to be relatively high.
Eighty-six percent of people buying HealthCare.gov plans had at least three insurance companies to choose from this year.
Technical analyst Todd Gordon sets his eyes on Amgen ahead of earnings.
Former Allergan CEO David Pyott tells a Senate hearing the SEC should investigate the Pershing Square-Valeant alliance.
Technical analyst Todd Gordon looks at Amgen ahead of its earnings report. Explains why the stock could be poised to rally.
GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.
States that expanded Medicaid programs saw bigger gains in insured rates, as well as access to doctors and medicines, than other states.
Customers of the largest state-run Obamacare exchange can see price cuts if they move out of their current plans.
The department is expected to grant a 10-year health-care IT pact, at up to $10 billion, to overhaul its electronic health system records.
Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.
One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.
Shares of Regeneron were down about 3 percent after the FDA approved Regeneron's cholesterol-lowering drug Praluent on Friday.
Get the best of CNBC in your inbox